Prevalence of debrisoquine oxidation phenotypes in glaucoma patients

@article{Salminen2005PrevalenceOD,
  title={Prevalence of debrisoquine oxidation phenotypes in glaucoma patients},
  author={L. Salminen and R. Lindberg and H. -. Toivari and R. Huupponen and T. Kaila and E. Iisalo},
  journal={International Ophthalmology},
  year={2005},
  volume={13},
  pages={91-93}
}
The oxidation of debrisoquine, a sympatholytic antihypertensive agent, exhibits genetic polymorphism. The debrisoquine/4-OH-debrisoquine metabolic ratio (MR) separates the population to poor (PM, MR>12.6) and extensive (EM, MR<12.6) metabolizers. 5–10% of the caucasians belong to the PM phenotype. The oxidation of many other drugs, like timolol, correlates with the debrisoquine phenotype.We determined the debrisoquine phenotype in 102 glaucoma patients. The majority of the patients was treated… Expand
2 Citations

References

SHOWING 1-10 OF 22 REFERENCES
Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
Polymorphic drug oxidation in humans.
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
The Polymorphic Oxidation of β-Adrenoceptor Antagonists
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Oxidation phenotype and the metabolism and action of beta-blockers
  • M. Lennard
  • Biology, Medicine
  • Klinische Wochenschrift
  • 2005
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Pharmacokinetics and beta‐blocking effects of timolol in poor and extensive metabolizers of debrisoquin
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
Physiological disposition and metabolism of timolol in man and laboratory animals.
...
1
2
3
...